Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
A new therapeutic concept, which utilizes dynorphin-based gene therapy, has been developed and could suppress seizures at their site of origin and on demand.
Physician and patient treatment decision-making in relapsing–remitting multiple sclerosis in Europe and the USA
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
In this editorial, we shed light on the key advances made in migraine genetics, their neurobiology and what the future might hold for the field.
New research suggests that exosomes could play an important role in brain circuits, cell signaling and cell communication.
The first global report on epilepsy has been published by the WHO, which calls for action to make the condition a public health priority.
In this ‘Ask the Experts’ series, we’ve brought together a panel of researchers to discuss gene therapies in neurological diseases in a two-part discussion.